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Abstract
Purpose Florbetapir (AV-45) has been shown to be a reliable
tool for assessing in vivo amyloid load in patients with
Alzheimer’s disease from the early stages. However, nonspe-
cific white matter binding has been reported in healthy sub-
jects as well as in patients with Alzheimer’s disease. To avoid
this issue, cortical quantification might increase the reliability
of AV-45 PET analyses. In this study, we compared two
quantification methods for AV-45 binding, a classical method
relying on PET template registration (route 1), and a MRI-
based method (route 2) for cortical quantification.
Methods We recruited 22 patients at the prodromal stage of
Alzheimer’s disease and 17 matched controls. AV-45 binding
was assessed using both methods, and target-to-cerebellum
mean global standard uptake values (SUVr) were obtained for
each of them, together with SUVr in specific regions of
interest. Quantification using the two routes was compared
between the clinical groups (intragroup comparison), and
between groups for each route (intergroup comparison). Dis-
criminant analysis was performed.
Results In the intragroup comparison, differences in uptake
values were observed between route 1 and route 2 in both
groups. In the intergroup comparison, AV-45 uptake was
higher in patients than controls in all regions of interest using
both methods, but the effect size of this difference was larger
using route 2. In the discriminant analysis, route 2 showed a
higher specificity (94.1 % versus 70.6 %), despite a lower
sensitivity (77.3 % versus 86.4 %), and D-prime values were
higher for route 2.
Conclusion These findings suggest that, although both quan-
tification methods enabled patients at early stages of
Alzheimer’s disease to be well discriminated from controls,
PET template-based quantification seems adequate for clinical
use, while theMRI-based cortical quantificationmethod led to
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greater intergroup differences and may be more suitable for
use in current clinical research.
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Introduction
Alzheimer’s disease (AD) is a major current public
health issue and has been the target of numerous clin-
ical studies in recent decades to improve its diagnosis
from the earliest stages, and to develop new therapies to
slow its progression. The diagnosis of probable AD
relies on clinical criteria that are constantly being up-
dated [1, 2]. Early diagnosis of AD, in particular at the
prodromal stage – when the first symptoms appear – is
now also possible in clinical research thanks to
established research criteria based on multimodal assess-
ments. These include amyloid pathology assessment
using various methods, such as cerebrospinal fluid
(CSF) sampling or amyloid-specific imaging by PET
[2, 3]. Several amyloid ligands have been studied
in vivo, two of which are widely used in current clin-
ical research: [11C-]PiB [4] and [18F-]Florbetapir (AV-
45) [5]. Both have now been proven to be reliable tools
for assessing the amyloid burden in the brain of patients
with AD compared to healthy controls [6–11]. Our
group has recently published a study on AV-45 binding
in patients with prodromal AD [12], and a case report
showing amyloid pathology using AV-45 PET imaging
during presymptomatic stages of AD [13].
As the present research criteria include amyloid bio-
markers, and now that the Food and Drug Administra-
tion [14] and the European Medicines Agency (http://
www.ema.europa.eu/) have approved the use of AV-45
imaging for clinical purposes [15], it is important to seek out
the most reliable method for analysing AV-45 imaging. Most
research studies have investigated AV-45 uptake using quan-
tification methods based on target-to-cerebellum standard up-
take values (SUVr) [5, 8, 16]. Nonspecific AV-45 binding has
been reported in white matter [9]. This nonspecific binding
may affect AV-45 quantification when using whole-brain
analyses. To avoid this issue, a few studies have started to
focus on AV-45 binding in grey matter only [17, 18]. In their
study, Rodrigue et al. excluded white matter from their anal-
yses by using AV-45 images from young healthy subjects as
masks assuming that no specific binding would be found in a
young healthy population [18]. In another recent study, La
Joie et al. applied a grey matter mask to AV-45 images that
were normalized in MNI space [17].
In the present study, we compared two methods for AV-45
cortical quantification, the first one quantifying regional mean
SUVr measured using an AV-45 template, and the second an
optimized method based on cortical signal extraction of SUVr
using individually segmented T1 MRI sequences.
Materials and methods
Participants
All participants gave their written informed consent. The
study was approved by the local ethics committee (Comité
de Protection des Personnes Sud-Ouest et Outre-Mer I) and
the French Agency for the Safety and Security of Medical
Devices (Agence Française de Sécurité Sanitaire des Produits
de Santé, reference A90605-58).
For this study, patients over 65 years old and with AD
at the prodromal stage [3] were recruited. They were all
recruited from the outpatient memory clinic (Neurology
Department, University Hospital, Toulouse, France).
Matched cognitively normal (CN) subjects were recruited
from among patients’ relatives or using recruitment post-
ing in public places. All participants underwent a neuro-
psychological and a medical assessment, brain MRI, FDG
PET and AV-45 PET imaging. CSF sampling was also
performed in patients only. To be included in the study,
patients had to show preserved autonomy in daily life
(Clinical Dementia Rating ≤0.5) but a memory complaint
of more than 6 months duration attested to by isolated
memory impairment on neuropsychological assessment
[19] and one or more of the following features:
& Medial temporal lobe atrophy assessed on MRI scan (se-
quences detailed below)
& Temporoparietal hypometabolism pattern on cerebral
FDG PET scan (classical clinical acquisitions)
& Abnormal CSF biomarkers according to published criteria
[20, 21]
Patients were not included if they had a concomitant
neurological or psychiatric disease, or if they were
affected by any clinically significant pathology that
could explain the memory complaint. Significant white
matter hyperintensities found on T2-weighted MRI im-
ages were a reason for exclusion.
CN subjects were included if they had no memory com-
plaint, no neurological or psychiatric disease history, and if
they had no first-degree relatives with AD. They were exclud-
ed if they showed significant white matter hyperintensities on
T2-weighted MR images or any cognitive impairment on
neuropsychological assessment.
More details on this population recruitment have been
published elsewhere [12].
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MRI and AV-45 acquisitions
Brain MRI scans
MRI scans were performed in all participants using a 3-T
imager (Intera Achieva; Philips, Best, The Netherlands).
High-resolution anatomical images using a 3-D T1-weighted
sequence (in-plane resolution 1 × 1 mm, slice thickness 1 mm,
repetition time/echo time/inversion time 8,189/3.75/
1,012.2 ms, flip angle 8°, field of view 240 × 256, and 160
contiguous slices) and a T2-weighted sequence (reconstructed
resolution 0.45 × 0.45 × 3 mm, repetition time/echo time
4,132/80 ms, flip angle 90°, field of view 240 × 184, and 43
slices) were obtained. CN subjects underwent the same MRI
acquisitions as patients.
AV-45 PET scans
All participants underwent a PET scan using AV-45 amyloid
marker. All scans were performed on the same hybrid PET/CT
scanner (Biograph 6 TruePoint Hirez; Siemens Medical Solu-
tions) using 3-D detection mode producing images with
voxels of 1×1×1.5 mm and a spatial resolution of approxi-
mately 5 mm full-width at half-maximum at the centre of the
field of view). Both CT and PET scans were acquired. Cere-
bral emission scans were started 50 min after injection of
3.7 MBq/kg weight of AV-45 and lasted for 20 min. PET data
were corrected for partial volume effects using the point
spread function (PSF) modelling implemented by Siemens
(HD-PET©). Briefly the manufacturer previously measured
the response of a point source from many points in its FOV
and incorporated measured PSFs in the reconstruction algo-
rithms. Using measured PSFs, HD-PET effectively positions
the lines of response in their actual geometric location, which
reduces blurring and distortion in the final images.
Three independent raters (two nuclear medicine physicians
and one radiologist physicist) with extensive experience read-
ing AV-45 PET scans, blind to clinical information, examined
all PET scans. A two-point rating scale (0 normal, 1 amyloid-
positive) was used. AV-45 PET scans were considered
amyloid-positive when the rating score was 1 for at least two
raters. The maximum delay between the two imaging exam-
inations was 3 months.
Image processing
Route 1: Template-based AV-45 quantification
AV-45-PET scans were linearly registered with 12 degrees of
freedom (DOF) and trilinear interpolation onto a template
from Avid (http://www.avidrp.com/), which is in the
Montreal Neurological Institute (MNI) space, using FLIRT
(FSL library tools) [22].
Regional cortical AV-45 mean SUV was measured in each
subject using a Matlab (The MathWorks®) script developed
in-house (Fig. 1a).Mean global SUVs, SUVs in the five lobes,
and SUVs in specific regions of interest (ROIs: orbitofrontal,
anterior cingulate, posterior cingulate and precuneus) were
calculated. These regions were selected as they have shown
different AV-45 binding in studies comparing AD patients to
CN subjects [8, 9, 12, 16, 23]. These regions were defined
using the anatomical automatic labelling (AAL) atlas [24]
provided by MRIcron software, that was linearly registered
(12 DOF, trilinear interpolation) onto the AV-45 template and
binarized. To minimize the bias due to nonspecific white
matter binding, the AAL atlas was masked for grey matter.
To do so, we used the greymatter probability map from SPM8
(Wellcome Trust Centre for Neuroimaging, London, UK), that
was binarized using a threshold of 0.3 – meaning that only
voxels with a probability greater than 30 % of being grey
matter were selected.
SUVs were then normalized (SUVr) to the whole cerebellar
mean uptake (vermis excluded) using Matlab and pooled by
group for statistical comparison (Fig. 1a).
Route 2: Cortical MRI-based AV-45 quantification
Greymatter was segmented from the 3-D T1 anatomical image
of each participant using FASTand FIRST (FSL library tools),
and the resulting grey matter mask was binarized using a
threshold of 0.3 – as used for route 1 [25]. Then, for each
subject, the CT scan obtained during PET data acquisition was
linearly registered (12 DOF) onto the relative T1 anatomical
image. The transformation matrix obtained was applied to the
AV-45 image of the subject so that the AV-45 image was in the
T1 space. The grey matter mask from T1 segmentation (see
above) was applied to the transformed AV-45 image. The AAL
atlas [24] was also registered fromMNI space to each individ-
ual T1 space. To do this, the linear transformation matrix from
the registration of each single subject’s T1 ontoMNI space was
first calculated. The inverse of this matrix was then applied for
each subject to the AAL atlas to obtain ROIs in the subject’s
space. Finally, the registered atlases were binarized.
The cerebral regions studied were the same as those studied
in route 1. Values of regional cortical AV-45 mean SUV were
obtained for each subject using the same Matlab script as in
route 1 (Fig. 1b). SUVs were normalized (SUVr) to the whole
cerebellar mean uptake (vermis excluded, identical definition
to that used in route 1) and pooled by group for statistical
comparison.
Statistical analyses
The threshold for significance was set at p <.05. For the
neuropsychological assessments, groups were compared
using the Mann-Whitney or chi-squared statistical tests. A
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parametric paired t test with Bonferroni-Holmes correction
for multiple comparisons was used to compare SUVr values
between the two routes for both groups and to compare
regional uptake differences between groups for both quantifi-
cation methods. The effect sizes were assessed using Cohen’s
d [26]. Standard deviations were weighted by sample size as
the number of participants was not equal between groups [27].
For discriminant analysis of the imaging data from both
methods, receiver operating characteristics analyses were per-
formed on the mean global SUVr values to study the diagnos-
tic power. The areas under the curve (AUC) were calculated
and sensitivity and specificity were computed at the optimal
cut-off points. D-prime values as well as their associated bias
measures C were also computed for several cut-off values: the
value leading to the same sensitivity and specificity for both
routes, the value leading to the best sensitivity and specificity
trade-off for route 1, and the value leading to the best sensi-
tivity and specificity trade-off for route 2.
Results
Twenty-two patients with prodromal AD and 17 CN subjects
were included in the study (see supplementary data 1 for
individual profiles on research criteria). The two groups were
matched for age and level of education (see Table 1 for clinical
and neuropsychological data).
Visual assessment of AV-45 PET scans revealed amyloid-
positive profiles in 18 patients out of 22, and in 2 CN subjects
out of 17.
Fig. 1 AV-45 quantification procedures: a cortical PET template-based
(route 1) and b cortical MRI-based (route 2). a In route 1, AV-45
acquisitions were linearly registered onto a template from Avid (http://
www.avidrp.com/), and regional uptakewas quantified for each subject in
the MNI space using the AAL atlas [24] that was masked with a grey
matter probability map. Uptake values were collected using Matlab. b In
route 2, for each subject, the CT scan acquired together with the AV-45
image was registered onto the MRI anatomical space defined by the T1
image of the subject concerned (1). The transformation matrix obtained
was then applied to the AV-45 image of the subject so that the AV-45
image was in the T1 space (2). A binarized grey matter mask obtained
fromMRI segmentation was applied to the transformedAV-45 image (3).
The AAL atlas was also registered onto each individual T1 space using
the inverse of the transformation matrix from the T1 registration onto
MNI space (4). Regional cortical uptake was collected for each subject
using Matlab (5). Arrows represent transformation (Subj subject)







Age (years) 72.4±5.0 69.9±4.8 .110
Gender (M/F) 12/10 7/10 .408
Level of education (years) 11.3±2.7 12.8±3.3 .163




Global cognitive state (MMSE) 25.7±1.4 28.4±.7 <.001*
Anterograde verbal memory (FCSRT test)
Sum of free recalls (/48) 11.6±5.9 32.2±4.6 .001*
Sum of free and cued
recalls (/48)
28.7±11.9 46.6±1.9 .001*
CDR Clinical Dementia Rating, FCSRT Free and Cued Selective Recall
Reminding test
*p <.05
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Comparison of SUVr values between the two routes for both
groups
In the patient group, regional SUVr values in the insula and
the orbitofrontal region were significantly lower using route 1
than route 2, while SUVr values in the posterior cingulate
were significantly higher using route 1. In the CN group, mean
global as well as frontal, parietal and posterior cingulate SUVr
values were significantly higher using route 1 than route 2
(Table 2).
Imaging comparison between groups
Both methods showed significantly higher AV-45 uptake in
the patient group than in the CN subjects in all ROIs.
Route 1 (AV-45 template-based quantification)
Compared to the CN subjects, the patients showed a signifi-
cantly higher uptake of AV-45 in the whole brain (p =.002), in
every cerebral lobe (frontal p =.013, parietal p =.001,
temporal p =.003, insula p =.007, occipital p =.008) and each
ROI (orbitofrontal p =.018, anterior cingulate p =.010, poste-
rior cingulate p =.014, precuneus p <.001; Fig. 2a).
Route 2 (MRI-based AV-45 quantification)
Compared to the CN group, the patients group showed a
significantly higher uptake of AV-45 in the whole cortex
(p <.001), in every cerebral lobe (frontal p =.002, parietal
p = .001, temporal p = .001, insula p = .002, occipital
p =.003), and each ROI (orbitofrontal p =.002, anterior cingu-
late p =.001, posterior cingulate p =.001, precuneus p <.001;
Fig. 2b).
Effect size
AV-45 uptake was higher in patients than in CN subjects with
both methods. Cohen’s d values were calculated for all re-
gions. They were always higher with route 2 than with route 1
(Fig. 2).
Table 2 Comparison between
the two quantification methods
for both groups. AV-45 mean
global and target-to-cerebellum
SUVr values and associated stan-
dard deviations are shown for the
two groups using PET template-
based quantification (route 1) and
MRI-based quantification (route
2). Significant p values (<.05) are
shown
Region Patients CN subjects
Route 1 Route 2 p value Route 1 Route 2 p value
Global 1.47±.24 1.50±.32 – 1.25±.13 1.18±.09 .010
Frontal lobes 1.49±.28 1.54±.38 – 1.29±.17 1.19±.13 .010
Temporal lobes 1.42±.22 1.45±.30 – 1.19±.13 1.16±.07 –
Insular lobes 1.37±.27 1.46±.32 .045 1.14±.13 1.19±.11 –
Parietal lobes 1.54±.25 1.51±.35 – 1.26±.14 1.15±.09 .002
Occipital lobes 1.43±.22 1.49±.31 – 1.24±.13 1.22±.08 –
Orbitofrontal 1.47±.31 1.60±.41 .011 1.22±.17 1.23±.16 –
Anterior cingulate 1.59±.31 1.67±.41 – 1.36±.20 1.30±.16 –
Posterior cingulate 1.82±.31 1.74±.36 .021 1.55±.27 1.36±.14 .005
Precuneus 1.56±.30 1.56±.36 – 1.20±.14 1.14±.09 –
Fig. 2 Target-to-cerebellum cortical AV-45 uptake ratios using a route 1
(the PET template-based method) and b route 2 (the MRI-based method).
Mean values in all ROIs are shown with associated standard deviations
(red diamonds patients, green circles control subjects) *p <.05, **p<.01,
***p <.001. Cohen’s d values for each region are given in red
characters
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Discriminant analysis
Discriminant analysis of the mean global AV-45 SUVr values
from route 1 showed the highest sensitivity (86.4 %) and
specificity (70.6 %) with a cut-off value of 1.67 (AUC 0.81).
For this cut-off value, D-prime was 1.64 for route 1 and 2.31
for route 2 (Fig. 3).
In contrast, discriminant analysis of the mean global AV-45
SUVr values from route 2 showed the highest sensitivity
(77.3 %) and specificity (94.1 %) with a cut-off value of
1.28 (AUC 0.81). For this cut-off value, D-prime was 1.32
for route 1 and 2.31 for route 2 (Fig. 3).
Discussion
In this study, we compared two quantitative methods for
assessing cortical AV-45 target-to-cerebellum uptake in a pop-
ulation of patients with prodromal AD matched to CN sub-
jects. Route 1 relied on cortical quantification using a stan-
dardized PET template. Route 2 relied on cortical uptake
using cortical signal extraction from individual MRI se-
quences.We showed that (1) there were significant differences
between the SUVr values from route 1 and route 2 in the
patients and CN groups; (2) global quantification relying on
the cortex only (route 2) showed a greater difference between
SUVr of prodromal patients and SUVr of CN subjects than the
template-based registration (route 1). To our knowledge, this
is the first study showing significant differences between PET
template-based and MRI-based cortical AV-45 quantification
methods.
Patients were included if they were diagnosed with prodro-
mal AD according to research criteria [3]. Amyloid burden is
thought to appear early, before the first clinical symptoms, and
to have reached a high level at the prodromal stage. In this
study, both methods showed significantly higher AV-45 up-
take in prodromal patients than in matched CN subjects, both
global uptake and uptake in all neocortical regions.
To avoid interference from white matter uptake in our
quantification methods, we used grey matter masks. However,
the same mask was used for all PET images in route 1, all
being in MNI space, while a specific grey matter mask was
used for each participant derived from segmentation of the
subject’s ownMRI scan in route 2, potentially leading to more
precision in cortical quantification. This may be the reason for
significant differences observed between the two routes. In the
CN group there were significant decreases in global uptake
and in frontal, parietal and posterior cingulate uptakes using
route 2 compared to route 1. It is known that CN subjects
show important nonspecific AV-45 binding in white matter,
which may affect whole-brain quantification. Our PET
template-based quantificationmethod (route 1) may have only
partially suppressed the effect of white matter uptake, while
the individual MRI-based method (route 2) produced lower
cortical SUVr values in CN subjects. Similar results were
found for the posterior cingulate region in the patient group,
with significantly lower uptake found using route 2. One
hypothesis that may be proposed is that the white matter
PET signal could easily spill over onto the posterior cingulate
because of the latter’s proximity to dense white matter fibres.
As in the CN subjects, the MRI-based method would mini-
mize the effect of white matter uptake in this region in pa-
tients. We also found significant increases in the uptake values
Fig. 3 Receiver operating
characteristics curves for route 1
and route 2 (a orange curve route
1, green curve route 2). b–d D-
prime values and the
corresponding values of the bias
measure C for three different
SUVr values: b cut-off value for
same sensitivity/specificity for
route 1 and route 2, c cut-off
value for best sensitivity/
specificity for route 1, d cut-off
value for best sensitivity/
specificity for route 2
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in the insula and the orbitofrontal regions of patients when using
route 2. This may be due to high specific amyloid binding that
would be reduced by some white matter signal “surviving” in
route 1. Further studies testing such hypotheses are necessary.
We used MRI for individual grey matter segmentation
since classical T1-weighted MRI sequences have higher res-
olution than PET images and since most patients nowadays
undergo clinical MRI scans for diagnostic purposes. Many
studies on amyloid imaging have used visual assessment to
determine the uptake profiles of amyloid markers and to
classify subjects as “positive” or “negative”. Although it
may be the fastest way so far found to assess AV-45 uptake
profiles in clinical routine, visual assessment has shown some
limitations [28] and should be considered with caution. The
use of SUV quantification, and in particular cortical quantifi-
cation, should provide more precise results. It is thus crucial to
develop fast, reproducible techniques.
A recent study investigated similar questions regarding
analyses of amyloid PET imaging using PiB in AD patients
and CN subjects [25]. The authors compared a method using a
PiB template for normalization, and one method using MRI
for grey matter segmentation and normalization. Both
methods included transformation into MNI space – which
was not the case in our study. The authors showed that the
PET template-based and MRI-based methods were slightly
different, with systematically higher, but comparable, values
for the PET template-based method in every group. In our
study, the results of our two methods were not comparable.
Route 2 (MRI-based method) showed greater differences and
a larger effect sizes of the cortical SUVr values of prodromal
AD patients and CN subjects than route 1. However, we used
a different approach to that of Edison et al. regarding theMRI-
based method, as we performed our analyses in the individual
space in all subjects to stay closest to the individual grey
matter anatomy. Such MRI-based cortical quantification
would thus lead to greater accuracy in individual regional
quantification. Besides, our study used the amyloid biomarker
AV-45, which has shown higher nonspecific binding than PiB
[16]. This could also partly explain the significant differences
we found between route 1 and route 2 that were not found by
Edison et al. [25]. In another recent study, Landau et al.
investigated amyloid ligand uptake using PiB and AV-45 in
a patients with mild cognitive impairment compared to
healthy subjects [29]. They used similar methods to our routes
1 and 2 for cortical quantification, and found similar results
between the two routes. These results, at oddswith ours, might
be accounted for by differences in the size of the selected ROIs
in the two studies.
On discriminant analysis, the two routes showed different
patterns. Route 1 showed a higher sensitivity than route 2
(86.4 % versus 77.3 %, respectively), but a lower specificity
(70.6 % versus 94.1 %, respectively). The high specificity of
route 2 corresponds to only one false-positive result, which is
in accordance with results of other studies [10, 30, 31]. This
means that a cortical MRI-based quantification gives fewer
false-positive results among CN subjects, and may be more
suitable for use in clinical research. On the other hand, the
conventional AV-45 template-based method gave fewer false-
negative results among patients. As a consequence, such a
method appears adequate for clinical use if the aim is to
confirm the diagnosis in patients presenting with other
markers suggestive of AD. The D-prime calculation showed
higher values for route 2, suggesting an overall better quality
of prediction usingMRI-based quantification. Bias measure C
confirmed the tendency of route 1 to be sensitive, as opposed
to the tendency of route 2 to be specific. Of note, visual
assessment showed discrimination results in between, with a
sensitivity of 81.8 % and a specificity of 88.2 %.
Conclusion
This study demonstrated that both cortical MRI-based and
PET template-based AV-45 quantifications efficiently dis-
criminate between prodromal patients and healthy subjects.
Clinical diagnosis may rely on PET template-based quantifi-
cation as it discriminates better between patients and healthy
subjects and it is faster and cheaper to perform than MRI-
based quantification. On the other hand the latter would be
more suitable for research purposes, as only 1 out of 17 CN
subjects was misclassified. A further AV-45 quantification
study including a larger sample should be performed.
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